First Time Loading...

Ascletis Pharma Inc
HKEX:1672

Watchlist Manager
Ascletis Pharma Inc Logo
Ascletis Pharma Inc
HKEX:1672
Watchlist
Price: 1.35 HKD -2.88% Market Closed
Updated: May 17, 2024
Section:
 

Relative Value

The Relative Value of one Ascletis Pharma Inc stock under the Base Case scenario is 0.88 HKD. Compared to the current market price of 1.35 HKD, Ascletis Pharma Inc is Overvalued by 35%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
0.88 HKD
Overvaluation 35%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

23
P/S
P/S
Price to Sales
23
vs History
44
vs Industry
31
Median 3Y
31.8
Median 5Y
0
Industry
8.2
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-14.9
Median 5Y
0
Industry
26.1
Forward
-6.3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-23.9
Median 5Y
0
Industry
24.8
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-20.7
Median 5Y
0
Industry
23.4
More Details
0.6
P/B
P/B
Price to Book Value
0.6
vs History
73
vs Industry
72
Median 3Y
0.9
Median 5Y
0.9
Industry
2.6
More Details
Negative
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
Median 3Y
-9
Median 5Y
0
Industry
7.4
More Details
Negative
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
9
Median 3Y
2
Median 5Y
0
Industry
9.1
More Details
3.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
3.5
vs History
3
vs Industry
12
Median 3Y
-4.1
Median 5Y
0
Industry
4.6
Forward
3.5
More Details
3.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
3.3
vs History
1
vs Industry
11
Median 3Y
-3.8
Median 5Y
0
Industry
4.4
Forward
3.2
More Details
6.9
EV/OCF
EV/OCF
Enterprise Value to OCF
6.9
vs History
1
vs Industry
13
Median 3Y
-4.7
Median 5Y
0
Industry
6.4
More Details
6.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
6.1
vs History
1
vs Industry
9
Median 3Y
-4.2
Median 5Y
0
Industry
3.8
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
-0.6
Industry
4.9
More Details

Multiples Across Competitors

Competitors Multiples
Ascletis Pharma Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Ascletis Pharma Inc
HKEX:1672
1.4B HKD 23 -9 3.5 3.3
US
Abbvie Inc
NYSE:ABBV
293.5B USD 5.4 60.9 13.2 20.1
US
Amgen Inc
NASDAQ:AMGN
167.5B USD 5.7 44.5 18.7 30.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.7B USD 11.6 31.7 25.7 26.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
108B USD 8.3 28.1 22.6 25.1
AU
CSL Ltd
ASX:CSL
135.3B AUD 6.4 36.6 22.1 27.4
US
Gilead Sciences Inc
NASDAQ:GILD
84.1B USD 3.1 173.7 7 9.2
US
Moderna Inc
NASDAQ:MRNA
50.7B USD 9.8 -8.5 -9.4 -8.3
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Biogen Inc
NASDAQ:BIIB
33.5B USD 3.5 28.7 14.6 18.2
KR
Celltrion Inc
KRX:068270
39.7T KRW 18.2 74.1 45.3 62.4
P/E Multiple
Earnings Growth
CN
Ascletis Pharma Inc
HKEX:1672
Average P/E: 59.8
Negative Multiple: -9 		N/A
US
Abbvie Inc
NYSE:ABBV
60.9
405%
US
Amgen Inc
NASDAQ:AMGN
44.5
82%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.7
49%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
28.1
45%
AU
CSL Ltd
ASX:CSL
36.6
84%
US
Gilead Sciences Inc
NASDAQ:GILD
173.7
75%
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -8.5 N/A
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -57.5 N/A
US
Biogen Inc
NASDAQ:BIIB
28.7
155%
KR
Celltrion Inc
KRX:068270
74.1
105%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 138,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.